The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review

Jolfaie, Nahid Ramezani; Mirzaie, Safiye; Ghiasvand, Reza; Askari, Gholamreza; Miraghajani, Maryam

doi:10.4103/1735-1995.170634

Cited by 23 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…enterocytes and lymphocytes). 2,5 It contains two ammonia groups: glutamate and ammonia. 3 GLN transports ammonia in a non-toxic form, from the peripheral tissue to visceral organs, where it is excreted in the urine.…”

Section: Introductionmentioning

confidence: 99%

“…3 It is also found in smaller amounts in the lungs and brain. 4,5 Good dietary sources of GLN are dairy, fish and green leafy vegetables. 3 GLN depletion occurs under catabolic conditions, such as cancer, injury and infection.…”

Section: Introductionmentioning

confidence: 99%

“…11 Oral GLN alone appeared to have no effect on mortality, 20,22 infections, time to neutrophil recovery, or relapses. 22 Oral GLN may reduce some chemotherapy-induced complications, such as mucositis and diarrhoea, among colon and colorectal cancer patients, 5 especially among those on 5-fluorouracil/folinic acid chemotherapy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Glutamine and its use in selected oncology settings

Tydeman-Edwards

2017

South African Journal of Clinical Nutrition

View full text Add to dashboard Cite

This review summarises the latest evidence for the use of glutamine (GLN) in oncology taking cognisance of current systematic reviews and available guidelines. Various studies in adults suggest that GLN supplementation suppresses tumour growth, by restoring the function of natural killer cells; improves protein metabolism; and, possibly enhances the effect of cancer therapy. There is insufficient data on whether GLN supplementation reduces the incidence of infection, although a trend exists towards such a reduction. GLN-supplemented enteral nutrition was superior in improving immune function, whilst oral GLN alone appeared to have no effect on: mortality; infections; time to neutrophil recovery; or, relapse. GLN significantly reduces the duration of diarrhoea, but had no effect on its prevention. Oral GLN may reduce the duration and severity of mucositis, with fewer days on opioid therapy. Oral GLN, but not intravenous GLN (IV-GLN), may decrease mucositis and graft-versus-host disease in adult bone marrow transplant patients. Currently, the evidence for reduction of severe mucositis or infection rate in children is not statistically significant, but GLN does significantly reduce parenteral nutrition use, reflecting a possible improvement in lower gut mucositis. Nevertheless, too few studies exist to either support or refute that GLN supplementation either reduces the duration of, or prevents the progression to, severe mucositis. In children, there is no significant evidence that IV-GLN supplementation reduces infection rates, hospital length of stay (LOS), graft-versus-host disease, or mortality. Children with solid tumours on chemotherapy receiving oral GLN supplementation showed significant improvements in some nutritional and immunological parameters, as well as the severity of stomatitis and need for antibiotic therapy. Caution is recommended when considering provision of IV-GLN to oncology patients who have hepatic or renal insufficiency or failure. Monitoring of hepatic and renal function is recommended. Further studies are needed specifically on the use of glutamine in an oncology setting. Larger, multicentre, randomised placebo-controlled studies are needed in both adult and paediatric oncology populations.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Glutamine and its use in selected oncology settings

Tydeman-Edwards

2017

South African Journal of Clinical Nutrition

View full text Add to dashboard Cite

show abstract

“…[2] Beside mentioned factors, diet has an important role in increasing or decreasing risks of some malignancy. [4567] Consistent evidence indicated that ovarian cancer has an inverse association with higher intakes of fruits and vegetables, whereas higher consumption of total fat and meat is widely associated with increased risk. [8] Moreover, some evidence was shown potential anticancer properties of flavonoids, protective chemicals in plant foods, such as antioxidant, anti-estrogenic, antiproliferative, and anti-inflammatory.…”

Section: Introductionmentioning

confidence: 99%

Quercetin and ovarian cancer: An evaluation based on a systematic review

Parvaresh

Razavi

Rafie³

et al. 2016

J Res Med Sci

Self Cite

View full text Add to dashboard Cite

Some studies have suggested chemopreventive and therapeutic effects of quercetin (Q) on carcinogenesis. The aim of this review was to evaluate the association between Q and ovarian cancer risk among human researches and induced sensitivity to some types of chemotherapeutic drugs and antiproliferative effects of this flavonoid in the animals and cell lines studies. Data for this systematic review were achieved through searches of the MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Cochrane, SID, and Magiran databases for studies published up to May 2015. Relevant studies were reviewed based on Preferred Reporting Item for Systematic Review and Meta analysis guidelines. From the total number of 220 papers obtained at the initial search, 13 publications including 1 prospective, 2 case -control, 1 animal, and 9 in vitro human and animal cancer cell lines studies were eligible. Despite findings in laboratory settings, results from the epidemiological studies commented that the potentially protective effects of Q not be able to significantly decrease ovarian cancer risk at levels commonly consumed (1.01–31.7 mg/day) in a typical diet. However, animal and in vitro studies suggest that Q exerts anticancer effects via inhibiting tumor growth, and angiogenesis, interrupt the cell cycle, and induce apoptosis. It is highlighted the need for more studies to be conducted.

show abstract

“…[4567] Most of the previous studies have focused on impact of nutrients[891011] or single dietary component on mortality or survival. [1213] However, nutrients or foods were not consumed individual.…”

Section: Introductionmentioning

confidence: 99%

Healthy eating index/alternative healthy eating index and breast cancer mortality and survival: A systematic review and meta-analysis

Pourmasoumi

Karimbeiki

Vosoughi

et al. 2016

Asia-Pacific Journal of Oncology Nursing

Self Cite

View full text Add to dashboard Cite

Objective:Breast cancer is the most common cancer in women worldwide. The effects of overall diet quality instead of single nutrients after breast cancer diagnosis on mortality have been a growing area of research interest. The aim of this systematic review was to investigate the relationship between the Healthy Eating Index (HEI)/the Alternative Healthy Eating Index (AHEI) and risk of breast cancer mortality or survival rates as a primary outcome, and some related inflammatory factors, as secondary outcomes among postdiagnosed women.Methods:This study methodology was performed based on the Preferred Reporting Item for Systematic Review and Meta-analysis statement recommendation and had been registered at PROSPERO (registration number: CRD42015015605). The systematic search was conducted in the electronic databases including PubMed, ISI, Scopus, Cochrane, and Google before July 2016. Researches that had not reported risk of breast cancer mortality or survival rates separately were excluded from the study. Similarly, this review excluded studies which only had examined the HEI or AHEI without reporting their association with the risk of mortality or survival rates.Results:After primary search, of 643 studies identified, 4 studies including eligible criteria were selected for the final assessment. All selected studies had been conducted in the USA and used self-report food-frequency questionnaire for diet quality assessment. In two studies HEI-2005, in one study AHEI, and in another study AHEI-2010 were applied. Meta-analysis result showed no significant association between these indexes and risk of breast cancer mortality/survival among women with this malignancy [relative risk: (RR) 1.04; 95% confidence interval (CI): 0.69–1.56; P = 0.87].Conclusions:Regarding the adherence HEI/AHEI, we found no association between mentioned indexes and risk of mortality or survival from breast cancer in women with breast cancer. However, evidence in this field is limited and inconsistence and further studies are needed.

show abstract

The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review

Cited by 23 publications

References 45 publications

Glutamine and its use in selected oncology settings

Glutamine and its use in selected oncology settings

Quercetin and ovarian cancer: An evaluation based on a systematic review

Healthy eating index/alternative healthy eating index and breast cancer mortality and survival: A systematic review and meta-analysis

Contact Info

Product

Resources

About